BioSpace News Archive

Deciphera Pharmaceuticals, Inc. announced that it will report its second quarter 2021 financial results on Tuesday, August 3, 2021.

IMIDomics Inc., a drug discovery company focused on patients with immune-mediated inflammatory diseases, has announced the completion of a $16.5 million Series A financing round.

XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, announced the completion of the Phase 1 dose-escalation component of its Phase 1/2 clinical trial of XC001, its lead investigational gene therapy candidate for patients with refractory angina who have no further treatment options.

Oragenics, Inc. announced it has entered into a licensing agreement with the National Research Council of Canada that will enable Oragenics to pursue the rapid development of next-generation vaccines against the SARS-CoV-2 virus and its variants.

iXensor Co., Ltd. (6734.TWO) launches the next generation of integrated COVID-19 screening solution, the PixoHealth Pass Admin App and Web Portal.

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity” or the “Company”), today presents data updates from MARIO-275, the Company’s randomized, placebo-controlled Phase 2 study evaluating the efficacy and safety of eganelisib in combination with nivolumab (Opdivo®) in platinum-refractory, I/O naïve patients with advanced UC as well as data from MARIO-3,

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 3, 2021 to report its second quarter 2021 financial results and provide a corporate update.

NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, announces that it will release its second quarter 2021 financial and operating results for the period ended June 30, 2021 on Tuesday, August 10, 2021 prior to the start of trading.

New patient adds for the U.S. TYMLOS business continue to grow. New TYMLOS patients in Q2, 2021 were up over 40% vs. the same period in 2020.

Talis Biomedical Corporation (“TLIS”), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced that it will release financial results for the second quarter after market close on Tuesday, August 10, 2021.